

---

## **CURRICULUM VITAE**

---

YIANNIS VASILOPOULOS

---

Ass. Professor of Genetics

---

## A. PERSONAL DETAILS

---

**NAME:** Yiannis Vasilopoulos

**DATE OF BIRTH:** 07.02.1980

**PLACE OF BIRTH:** Thessaloniki, Greece

**CONTACT DETAILS:** Email: [iovasilop@upatras.gr](mailto:iovasilop@upatras.gr)  
Department of Biology, Section of Genetics, Cell Biology and Development, University of Patras, GR-26500, Patras, Greece. Office (Room Number 260) Tel: +302610969243, Lab (Room Number 261) Tel: +302610969255.

**MARITAL STATUS:** Married

**CITIZENSHIP:** Greek

## B. EDUCATIONAL BACKGROUND

---

- **2006:** Ph.D “The role of proteases and protease inhibitors in the regulation of the skin barrier: genetic predisposition to atopic dermatitis and psoriasis (full-time studentship awarded by the University of Sheffield and Molecular SkinCare Ltd). Henry Wellcome Laboratories for Medical Research, Biomedical Genetics, Division of Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK.
- **2002:** MSc in Molecular and Genetic Medicine (Successful Completion with Distinction). Division of Genomic Medicine, University of Sheffield, UK.
- **2000:** B.Sc. (Honours) in Genetics (classification: 2.1). Institute of Biological Sciences, University of Wales, Aberystwyth, UK.

## C. TEACHING EXPERIENCE

---

**I. 2008-2016:** Visiting Lecturer – Under-graduate courses (P.D.407/80), Department of Biochemistry and Biotechnology and Department of Veterinary Science, University of Thessaly, Greece.

- **2017-2018:** Module: **Cellular and Molecular Biology** (Department of Veterinary science) (2<sup>rd</sup> semester).
- **2016-2018:** Module: **Genetics** (Department of Veterinary science) (1<sup>rd</sup> semester).
- **2015-2016:** Module: **Genetics** (3<sup>rd</sup> semester).
- **2015-2016:** Module: **Immunology** (6<sup>th</sup> semester).
- **2014-2015:** Module: **Genetics** (3<sup>rd</sup> semester).
- **2014-2015:** Module: **Molecular Basis of Human Diseases** (6<sup>th</sup> semester).
- **2009-2010:** Module: **General Biology** (1<sup>st</sup> semester).

- **2009-2010:** Module: **Immunology** (6<sup>th</sup> semester).
- **2009-2010:** Module: **Molecular Basis of Human Diseases** (6<sup>th</sup> semester).
- **2008-2009:** Module: **General Biology** (1<sup>st</sup> semester).
- **2008-2009:** Module: **Immunology** (6<sup>th</sup> semester).
- **2008-2009:** Module: **Molecular Basis of Human Diseases** (6<sup>th</sup> semester).

**II. 2008-2016:** Post-Graduate courses, Department of Biochemistry and Biotechnology, University of Thessaly, Greece.

### **1. MSc «Molecular Biology and Genetics applications-Diagnostic markers»: 2008-2016**

- Module: «*Genetics of human diseases*»:
  - Lecture: «Multifactorial diseases» - 3 hours
  - Lecture: «Pharmacogenetics» - 3 hours
- Module: «*Genome analysis, sequencing and chromosome analysis*»:
  - Lecture: «Genetic variation of human genome (HapMap and 1,000 Genomes)» - 3 hours
- Module: «*Cellular and Humoral Immunity*» - 3 hours
- Module: «*Molecular diagnosis of genetic and inflammatory disorders*»:
  - Lecture: «Molecular screening of multifactorial diseases» - 3 hours

### **2. MSc «Toxicology»: 2015-2016**

- Module: «*Systems toxicology – clinical trials*»:
  - Lecture: « Design of clinical trials » - 3 hours

**III. 2010-2016: Supervision of** >15 undergraduate and post-graduate students. Department of Biochemistry and Biotechnology, University of Thessaly, Greece.

.

**IV. 2005-2006:** Teaching assistant, «Module: Introduction in Dermatology and Clinical Research», Medical School, University of Sheffield, Sheffield, UK.

## **D. SCHLARSHIPS / AWARDS / PARTICIPATION IN RESEARCH PROGRAMS**

---

- **2015-2017:** Investigator-driven Research award, Novo Nordisc, “Pharmacogenetics of incretin-based therapies in Type II diabetes”, Medical School, Aristotle University, Thessaloniki, Greece. Scientific Coordinator: Ass. Prof. Kalliopi Kotsa.
- **2014-2015:** “ΑΡΙΣΤΕΙΑ ΙΙ” (ΕΣΠΑ-ΓΓΕΤ). «Integrated functional analysis of FRA10AC1, the chromosomal fragile site 10A causative gene – FRA-SYS». Scientific Coordinator: Prof. Nikolaos Moschonas.
- **2014:** «Genetics of Type II Diabetes – study of polymorphisms associated with Vitamin D metabolism and T2DM pathogenesis», Medical School, Aristotle University, Thessaloniki, Greece. Scientific Coordinator: Ass. Prof. Kalliopi Kotsa.

- **2014:** National award of Hellenic Society of Medical Genetics (one person per year) - National Fellowship of European Society of Human Genetics.
- **2009-2014:** Unrestricted research grant, Wyeth-Pfizer pharmaceuticals: «Genetics of Skin diseases», Department of Biochemistry and Biotechnology-Medical School University of Thessaly, Greece. Scientific Coordinator: Ass. Prof. Aggeliki Roussaki.
- **2006-2007:** “Integrated Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease (MUGEN)” European network of excellence LSHG-CT-2005-005203. Scientific Coordinator: Prof. George Kollias.
- **2002-2006:** PhD studentship, University of Sheffield, UK.

## E. OTHER ACTIVITIES

---

### I. MEMBER OF PROFESSIONAL SOCIETIES

- Hellenic Society of Biological Sciences.
- Hellenic Society of Medical Genetics.
- Hellenic Society of Biochemistry and Molecular Biology.
- European Society of Human Genetics.

### II. PATENTS

- Draft US provisional patent application-Application No. 61175960, Date of application: May 06, 2009 Title: “METHODS FOR TREATING INFLAMMATION”. Inventors: Georgios Kollias, Vasiliki Gkretsi, Yiannis Vasilopoulos.

### IV. JOURNAL REVIEWER (selected)

- Journal of Human Genetics
- The Pharmacogenomics Journal
- Genetic Testing and Molecular Biomarkers
- Cytokine
- Arthritis Research and Therapy

## F. RESEARCH INTERESTS

---

- **Gene-gene and gene-environment interactions in human multifactorial diseases.**
- **Pharmacogenetics/Pharmacogenomics of human autoimmune diseases.**
- **Functional genetics – *In vitro* and *in vivo* analysis of genes in inflammatory disorders for the identification of new therapeutic targets.**

## G. PUBLICATIONS

---

### I. MONOGRAPHY

The role of proteases and protease inhibitors in the regulation of the skin barrier: genetic predisposition to atopic dermatitis and psoriasis. Division of Genomic Medicine, Medical School, University of Sheffield, UK.

### II. BOOK CHAPTERS

Cork MJ, Danby S, **Vasilopoulos Y**, Moustafa M, MacGowan A, Varghese J, Duff GW, Tazi-Ahnini R & Ward SJ. Epidermal barrier dysfunction. Chapter 4, pp35-57. In: *Textbook of Atopic Dermatitis* (Series in Dermatological Treatment), by Reitamo S, Luger TA, Steinhoff M. Published by Informa Healthcare, 2008.

### III. ARTICLES

(in reverse chronological order)

(\*) corresponding author

1. Lopez-Rodriguez, R., Perez-Pampin, E., Marquez, A., Blanco, F. J., Joven, B., Carreira, P., **Vasilopoulos, Y**, ... & Cañete, J. D. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. *PLoS One* 2018; 13(5), e0196793.
2. **Vasilopoulos, Y**. Pharmacogenetics and psoriasis: is targeted treatment a possibility?. *Pharmacogenomics* 2017; Dec;18(18):1627-1630.
3. Goutzelas, Y., Kotsa, K., **Vasilopoulos, Y.**, Tsekmekidou, X., Stamatis, C., Yovos, J. G., ... & Mamuris, Z. Association analysis of FTO gene polymorphisms with obesity in Greek adults. *Gene* 2017; 613, 10-13.
4. Sarri, C. A., Roussaki-Schulze, A., **Vasilopoulos, Y.**, Zafiriou, E., Patsatsi, A., Stamatis, C., ... & Mamuris, Z. Netherton syndrome: a genotype-phenotype review. *Mol Diagn Ther* 2017; 21(2), 137-152.
5. Mendrinou E, Patsatsi A, Zafiriou E, Papadopoulou D, Aggelou L, Sarri C, Mamuris Z, Kyriakou A, Sotiriadis D, Roussaki-Schulze A, Sarafidou T, **Vasilopoulos Y\***. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF $\alpha$  inhibitors. *Pharmacogenomics J*. 2016 Apr 5
6. Ferreiro-Iglesias A, Montes A1, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, **Vasilopoulos Y**, Sarafidou T, ..... Gonzalez A. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. *Pharmacogenomics J*. 2016 Apr 16(2): 137-40.
7. Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, **Vasilopoulos Y**, Sarafidou T, ..... Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Gómez-Reino JJ, Gonzalez A. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. *Arthritis Res Ther*. 2015 Mar 18;17(1):63.
8. Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, Del Carmen Ordóñez M, Navarro-Sarabia F, Moreira V, **Vasilopoulos Y**, Sarafidou T, Caliz R, Ferrer MA, Cañete JD, de la Serna AR, Magallares B, Narváez J, Gómez-Reino JJ, Gonzalez A. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. *Pharmacogenomics*. 2015 Mar;16(4):333-45.

9. Márquez A, Aida Ferreira-Iglesias A, ....., **Vasilopoulos Y**, Sarafidou T, ....., Gonzalez A, Martin J. Lack of validation of genetic variants associated with anti-TNF therapy response in rheumatoid arthritis: a GWAS replication study and a meta-analysis. *Arthritis Res Ther.*, 2014; Mar 11;16(2):R66.
10. **Vasilopoulos Y\***, Sarri C, Zafiriou E, Patsatsi A, Stamatis C, Ntoumou E, Fassos I, Tsalta A, Karra A, Roussaki-Schulze A, Sotiriadis D, Mamuris Z, Sarafidou T. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. *Pharmacogenomics J.* 2014 Dec 14(6):523-25.
11. Montes A, Perez-Pampin E, Narvàez J, ....., **Vasilopoulos Y**, Sarafidou T, ....., Gonzalez A. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. *Pharmacogenetics and Genomics* 2014; May;24(5):238-45.
12. **Vasilopoulos Y\***, Sourli F, Zafiriou E, Klimi E, Ioannou M, Mamuris Z, Simos G, Koukoulis G, Roussaki-Schulze A. High serum levels of HIF-1 $\alpha$  in psoriatic patients correlate with an over-expression of IL-6. *Cytokine* 2013; 62(1):38-9.
13. **Vasilopoulos Y\***, Sarafidou T, Kotsa K, Papadimitriou T, Goutzelas Y, Bagiatis V, Stamatis C, Tsekmekidou X, Yovos JG, Mamuris Z. VDR Taq1 is associated with Obesity but not with Diabetes mellitus type 2 in the Greek population. *Gene* 2013; 512(2):237-9.
14. **Vasilopoulos Y\***, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Krüger-Krasagaki S, Tosca A, Patsatsi A, Sotiriadis D, Mamuris Z, Roussaki-Schulze A. Pharmacogenetic analysis of TNF, TNFRSF1A and TNFRSF1B polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. *Mol Diagn Ther* 2012; Feb 1;16(1):29-34.
15. **Vasilopoulos Y\***, Sarafidou T, Bagiatis V, Skriapa L, Goutzelas Y, Pervanidou P, Lazopoulou N, Chrousos GP, Mamuris Z. Association between polymorphisms in MTHFR and APOA5 and metabolic syndrome in the Greek population. *Genet Test Mol Bio* 2011; 15(9):613-7.
16. **Vasilopoulos Y\***, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I, Sarafidou T, Settas L, Sakkas L, Mamuris Z. Association of anti-CCP positivity and carriage of TNFR2 susceptibility variant with anti-TNF response in rheumatoid arthritis. *Clin Exp Rheumatol* 2011; 29(4):701-4.
17. **Vasilopoulos Y\***, Sagoo GS, Cork MJ, Walters K, Tazi-Ahnini R. HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction. *J Hum Genet* 2011; 56(6):423-7.
18. **Vasilopoulos Y\***, Sharaf N, di Giovine F, Ward SJ, Duff GW, Simon M, Cork MJ, Tazi-Ahnini R. The 3'-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis, causes an increased mRNA expression without altering its stability. *J Dermatol Sci* 2011; 61:131-3.
19. Cork MJ, Danby SG, **Vasilopoulos Y**, Hadgraft J, Lane ME, Moustafa M, Guy RH, MacGowan AL, Tazi-Ahnini R, Ward SJ. Epidermal Barrier Dysfunction in Atopic Dermatitis. *J Invest Dermatol* 2009; 129(8):1892-908.
20. Tazi-Ahnini R, McDonagh AJ, Wengraf DA, Lovewell TR, **Vasilopoulos Y**, Messenger AG, Cork MJ, Gawkrödger DJ. The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. *Br J Dermatol* 2008; 159(3):591-6.
21. **Vasilopoulos Y**, Walters K, Cork MJ, Duff GW, Sagoo GS, Tazi-Ahnini R. Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: Evidence for interaction between

PSORS1and PSORS5. *Eur J Hum Genet* 2008; 16(8):1002-9.

22. Wengraf DA, McDonagh AJ, Lovewell TR, **Vasilopoulos Y**, Macdonald-Hull SP, Cork MJ, Messenger AG, Tazi-Ahnini R. Genetic analysis of autoimmune regulator haplotypes in alopecia areata. *Tissue Antigens* 2008; 71(3):206-12.
23. Cork MJ, Danby S, **Vasilopoulos Y**, Moustafa M, MacGowan A, Varghese J, Duff GW, Tazi-Ahnini R, Ward SJ. Gene-environment interactions in atopic dermatitis. *Drug Discov Today: Dis Mech* 2008; 5(1).
24. **Vasilopoulos Y**, Gkretsi V, Armaka M, Aidinis V, Kollias G. Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis. *Ann Rheum Dis* 2007; 66 Suppl 3:iii23-8.
25. **Vasilopoulos Y**, Cork MJ, Teare D, Marinou I, Ward SJ, Duff GW, Tazi-Ahnini R. A non-synonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a strong association with atopic dermatitis. *Allergy* 2007; 62:514-19.
26. Cork MJ, Robinson DA, **Vasilopoulos Y**, Ferguson A, Mustafa M, Duff GW, Ward SJ, Tazi-Ahnini R. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene Environment Interactions. *J Allergy Clin Immunol* 2006; 118:3-21.
27. Cork MJ, Robinson DA, **Vasilopoulos Y**, Ferguson A, Mustafa M, Ward SJ, Tazi-Ahnini R. Predisposition to sensitive skin and atopic eczema. *Community Prac* 2005; 78:440-2.
28. **Vasilopoulos Y**, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, Ward SJ, Tazi-Ahnini R. Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme (SCCE) gene and atopic dermatitis. *J Invest Dermatol* 2004; 123:62-6.

Total Impact Factor = <b>110</b>
Mean Impact Factor = <b>4.237</b>
Citations > <b>1000</b>
Hirsch factor ( <i>h</i> ) = <b>12</b>
Journal Citation Report/ SCOPUS (2017).

#### IV. Conference Presentations/Papers

##### *In Proceedings of International Conferences:*

1. A. Ferreiro-Iglesias, A. Montes.....Y. Vasilopoulos, ..... J. J. Gómez-Reino, A. Gonzalez. Replication of GWAS of response to TNF inhibitors in patients with rheumatoid arthritis. **EULAR 2015 - Annual European Congress of Rheumatology (10-13 June, Rome, Italy). Ann Rheum Dis2015;74(Suppl2): 115.**
2. **Vasilopoulos Yiannis**, Sarri Constantina, Stamatis Costas, Zafiriou Efterpi, Roussaki-Schulze Angeliki, Patsatsi Aikaterini, Sotiriadis Dimitris, Mamuris Zissis, Sarafidou Theologia. ABCB1 haplotype construction and systems biology in a pharmacogenetic study of cyclosporine treatment response in Greek patients with

psoriasis. **European Conference of Human Genetics 2014 (31<sup>st</sup> May-3<sup>rd</sup> June, Milan, Italy). European Journal of Human Genetics 2014 Vol 22 (Suppl 1): 302.**

3. Ariana Montes, Eva Perez-Pampin, Federico Navarro-Sarabia, Virginia Moreiras, Arturo Rodríguez de la Serna, Berta Magallares, **Yiannis Vasilopoulos**, Theologia Sarafidou, Antonio Fernández Nebro, María del Carmen Ordóñez, Javier Narváez, Juan D Cañete, John Isaacs, Ann Morgan, Anne Barton, Anthony G Wilson, on behalf of BRAGGGSS, Juan J Gómez-Reino, Antonio Gonzalez. Less improvement in patients with Rheumatoid Arthritis showing IgG1 allotype incompatibility with Infliximab. **EULAR 2013 - Annual European Congress of Rheumatology (12-15 June, Madrid, Spain, UK). Ann Rheum Dis 2013;72(Suppl3):167.**
4. **Y. Vasilopoulos**, V. Bagiatis, D. Stamatopoulou, D. Zisopoulos, I. Alexiou, T. Sarafidou, L. Settas, L. Sakkas, Z. Mamuris. Association of anti-CCP positivity and carriage of TNFR2 susceptibility variant with anti-TNF response in rheumatoid arthritis. **EULAR 2011 - Annual European Congress of Rheumatology (25-28 May, London, UK). Ann Rheum Dis 2011;70(Suppl3):712.**
5. **Y Vasilopoulos**, M Manolika, E Zafiriou, T Sarafidou, V Bagiatis, S Krüger-Krasagaki, A Tosca, A Patsatsi, D Sotiriadis, Z Mamuris, A Roussaki-Schulze. Pharmacogenetic analysis of TNF $\alpha$  and TNFR2 polymorphisms and prediction to response to anti-TNF therapy in psoriasis patients in the Greek population. **20<sup>th</sup> Congress - European Academy of Dermatology and Venereology (Lisbon 20-24 October 2011).**
6. **Vasilopoulos Y**, Sagoo GS, Cork MJ, Walters K, Tazi-Ahnini R. HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction. **20<sup>th</sup> Congress - European Academy of Dermatology and Venereology (Lisbon 20-24 October 2011).**
7. **Vasilopoulos, Y.**, Cork, M.J., Sagoo, G.S., Ward, S.J., Duff, G.W., Tazi-Ahnini, R. A synonymous SNP in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. **British Society for Investigative Dermatology. Manchester April 2006. British Journal of Dermatology 2006 155, pp235.**
8. Cork M, Robinson D, **Vasilopoulos Y**, et al. Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. **J Am Acad Dermatol 56 (2): AB69 Suppl. S FEB 2007.**
9. **Vasilopoulos, Y.**, Cork, M.J., Murphy, R., Williams, H.C., Robinson, D.A., Duff, G.W., Ward, S.J., Tazi-Ahnini, R. Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme (SCCE) gene and atopic dermatitis. **British Society for Investigative Dermatology. Sheffield April 2004. British Journal of Dermatology, 150, pp805.**
10. R. Tazi-Ahnini, **Y. Vasilopoulos**, J.K. Henderson, R. Murphy, H. Williams, S.J. Ward, G.W. Duff, M.J. Cork. Role of variants within the skin barrier in the pathogenesis of atopic eczema. **British Association of Dermatologists. Brighton July 2003. British Journal of Dermatology 2003; 149 (Suppl. 64): 1-7.**

***In Proceedings of Greek Conferences:***

11. **Y. Vasilopoulos**, A. Patsatsi, E. Zafeiriou, D. Papadopoulou, L. Aggelou, A. Lyriakou, A. Roussaki-Schlze, D. Sotiriadis, Z. Mamuris, T. Sarafidou. The role of functional polymorphisms in Fc $\gamma$ RIIA and Fc $\gamma$ RIIIA genes in the treatment of psoriasis patients with Fc-containing TNF inhibitors in the Greek population. **11<sup>th</sup> Conference of the Hellenic Society of Dermatology and Venereology (Thessaloniki, 25-28 June, 2015).**
12. E. Mendrinou, **Y. Vasilopoulos**, E. Zafeiriou, A. Patsatsi, A. Roussaki-Schlze, D. Sotiriadis, Z. Mamuris, T. Sarafidou. A pharmacogenetic study of CYP3A4\*1B and CYP3A5\*3 polymorphisms in the treatment of psoriasis patients with cyclosporine in the Greek population. **11<sup>th</sup> Hellenic Conference of Dermatology and Venereology (Thessaloniki, 25-28 June, 2015).**



13. **Y. Vasilopoulos**, K. Sarri, K. Stamatis, E. Doumou, I. Fassos, A. Tsalta, A. Karra, E. Zafeiriou, A. Roussaki-Schlze, A. Patsatsi, D. Sotiriadis, Z. Mamuris, T. Sarafidou. A large multi-center pharmacogenetic study of ABCB1 gene polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. **64<sup>th</sup> Conference of the Hellenic Society of Biochemistry and Molecular Biology (Athens, 6-8 December, 2013).**
14. **Y. Vasilopoulos**, T. Sarafidou, X. Tsekmekidou, Y. Goutzelas, Z. Mamuris, J. Yiovos, K. Kotsa. Genetic association of Cdx2 polymorphism in the VDR gene with obesity and lower levels of Vitamin D in the greek population. **27<sup>th</sup> Annual Conference of the Hellenic Association of Northern Greece (ΔΕΒΕ) (Thessaloniki, 14-16 November, 2013).**
15. K. Sarri, **Y. Vasilopoulos**, K. Stamatis, E. Zafeiriou, A. Roussaki-Schulze, Z. Mamuris, T. Sarafidou. Identification of mutations in *SPINK5* in a patient with Netherton syndrome from Greece. **1<sup>st</sup> Conference of the Hellenic Society of Medical Genetics (Athens, 30 May-1 June, 2013).**
16. **Y. Vasilopoulos**, T. Sarafidou, I. Fassos, K. Sarri, K. Stamatis, E. Zafeiriou, A. Patsatsi, D. Sotiriadis, A. Roussaki-Schlze, Z. Mamuris. A pharmacogenetic association study of *C3435T* polymorphism in *ABCB1* gene with response to cyclosporine therapy in greek patients with psoriasis. **1<sup>st</sup> Conference of the Hellenic Society of Medical Genetics (Athens, 30 May-1 June, 2013).**
17. O. Karravia, **Y. Vasilopoulos**, T. Sarafidou, X. Tsekmekidou, K. Kotsa, Y. Goutzelas, K. Stamatis, J. Yiovos, Z. Mamuris. An association study of VDR CDx2 polymorphism and obesity in the Greek population. **35<sup>th</sup> Conference of the Hellenic Society of Biological Sciences (Nafplio, 23-25 May, 2013).**
18. I. Fassos, **Y. Vasilopoulos**, T. Sarafidou, K. Sarri, K. Stamatis, E. Zafeiriou, A. Patsatsi, D. Sotiriadis, A. Roussaki-Schlze, Z. Mamuris. A pharmacogenetic association study of *C3435T* polymorphism in *ABCB1* gene with response to cyclosporine therapy in greek psoriasis patients. **35<sup>th</sup> Conference of the Hellenic Society of Biological Sciences (Nafplio, 23-25 May, 2013).**
19. **Y. Vasilopoulos**, T. Sarafidou, E. Zafeiriou, E. Doumou, K. Stamatis, V. Bagaitis, A. Patsatsi, D. Sotiriadis, Z. Mamuris, A. Roussaki-Schlze. Pharmacogenetic study of polymorphisms in *ABCB1* and *MTHFR* genes and response to cyclosporine and methotrexate therapy in greek patients with psoriasis. **23<sup>rd</sup> Hellenic Conference of Rheumatology (Athens, 7-9 December, 2012).**
20. **Y. Vasilopoulos**, Y. Goutzelas, T. Sarafidou, K. Kotsa, K. Tsekmekidou, J. Yiovos, Z. Mamuris. Genetic association of Taq1 polymorphism in VDR and obesity in the greek population. **26<sup>th</sup> Annual Conference of the Hellenic Association of Northern Greece (ΔΕΒΕ) (Thessaloniki, 15-17 November, 2012).**
21. Sarri K, **Y. Vasilopoulos**, E. Zafeiriou, A. Roussaki-Schlze, Z. Mamuris, T. Sarafidou. Mutation analysis of *SPINK5* gene in a Greek patient with Netherton syndrome. **63<sup>rd</sup> Conference of the Hellenic Society of Biochemistry and Molecular Biology (Crete, 9-11 November, 2012).**
22. M Manolika, **Y Vasilopoulos**, E Zafiriou, T Sarafidou, V Bagiatis, S Krüger-Krasagaki, A Tosca, A Patsatsi, D Sotiriadis, Z Mamuris, A Roussaki-Schulze. Pharmacogenetic analysis of TNF $\alpha$  and TNFR $II$  polymorphisms and prediction to response to anti-TNF therapy in psoriasis patients in the Greek population. **33<sup>rd</sup> Conference of the Hellenic Society of Biological Sciences (Edessa, 13-15 May, 2011).**
23. **Y. Vasilopoulos**, E.M. Manolika, E. Zafeiriou, T. Sarafidou, V. Bagiatis, A. Patsatsi, D. Sotiriadis, S. Krasagaki, A. Toska, Z. Mamuris, A. Roussaki-Schulze. Pharmacogenetic association study of TNF $\alpha$  polymorphisms and response to anti-TNF therapy in patients with psoriasis in the greek population. **10<sup>th</sup> Conference of the Hellenic Society of Dermatology and Venereology (Athens, 23-26 June, 2011).**

- 24. Y. Vasilopoulos**, Gurdeep S Sagoo, Michael J Cork, Kevin Walters, Rachid Tazi-Ahnini. Gene-gene interaction between the genetic loci PSORS1 (CSTA), PSORS4 (HLA-Cw6) and PSORS5 (D1S2346) causes a x100 risk in the development of psoriasis. **10<sup>th</sup> Conference of the Hellenic Society of Dermatology and Venereology (Athens, 23-26 June, 2011).**
- 25. D. Stamatopoulou, Y. Vasilopoulos**, V. Bagiatis, D. Zisopoulos, I. Alexiou, T. Sarafidou, A.J. Wilson, L. Settas, L. Sakkas, Z. Mmauris. Pharmacogenetic association study between polymorphisms in TNF $\alpha$  gene and its receptors and response to anti-TNF $\alpha$  therapy in patients with rheumatoid arthritis. **21<sup>st</sup> Hellenic Conference of Rheumatology (Thessaloniki, 9-12 December, 2009).**